Saturday, February 28, 2015

Ebola Drug ZMapp in Trial Phase in Liberia

United States and Liberian government has started trial of Ebola drug ZMapp. It was previously used in peak times of deadly Ebola virus and helped rescue teams to keep away from infection. National Institute of Allergy and Infectios Diseases's director Dr. Anthony Fauci said that although medicine is beneficial for this virus but to make sure, clinical trial is important.


Dr. Anthony is enthusiastic to make ZMapp as proper treatment for Ebola virus. So that current and future patient can be treated at Liberian treatment centers with local staff. Clinical trial is divided in two phases and voluntary patients are admitted. One will be given ZMapp in treatment and other not. Both will be examined by medicine experts to get statistics that will help determine future course of drug.

US FDA is also in favor of this trial. Although many are against it but officials see it the only way to get a better treatment option. ZMapp is manufactured from monoclonal antibodies. These antibodies will attach to Ebola virus. There is possibility that these will make pathogen ineffective. Monoclonal antibodies grow in tobacco plants and made under researcher's team of Mapp Biopharmaceutical Inc. of San Diego - USA.

Related Stories: